A dominant selectable marker for gene transformation and disruption in yeasts
CA 2400534 C · Owner: Davison, John · Inventors: Davison, John; Bussey, Howard; Roemer, Terry
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a novel dominant selectable marker system in yeast that is based on an aminoglycoside nourseothricin (NST). This compound , possesses a powerful antifungal activity against Candida albicans and S. cerevisiae. The invention provides a cognate drug resistance marker for use in gene transformation and disruption experimentation in Candida albicans and Saccharomyces cerevisiae. In particular the invention presents: 1) direct , utility for gene manipulations in both clinically and experimentally relevant strains regardless of genotype and without affecting growth rate or hyphal , formation; and 2) applicability to antifungal drug discovery including target , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 19, 2001 and granted June 19, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 19, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 19, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.